Production of a Monoclonal Antibody Targeting the M Protein of MERS-CoV for Detection of MERS-CoV Using a Synthetic Peptide Epitope Formulated with a CpG–DNA–Liposome Complex

International Journal of Peptide Research and Therapeutics

Volumn 25, Issue 3, 2019, Pages 819-826

  Park, Byoung Kwon ^a   Lee, Su In ^a   Bae, Joon Yong ^b   Park, Man Seong ^b   Lee, Younghee ^c   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

B cell epitope; M protein; MERS CoV; Monoclonal antibody

Indexed keywords

CHOLESTEROL HYDROGEN SUCCINATE; CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; LIPOSOME; M PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M158 2D6F11; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; FEMALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; VIRUS DETECTION;

EID: 85049598107     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-018-9731-8     Document Type: Article

References (35)

1. Almazán F, DeDiego ML, Sola I et al (2013) Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio. 10.1128/mBio.00650-13
2. Anderson RM, Fraser C, Ghani AC et al (2004) Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic. Philos Trans R Soc Lond B 359(1447):1091–1105
3. Du L, Zhao G, Yang Y et al (2014) A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 88(12):7045–7053
4. Durai P, Batool M, Shah M, Choi S (2015) Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med 47:e181
5. Gao J, Lu G, Qi J et al (2013) Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 87(24):13134–13140
6. Girard MP, Cherian T, Pervikov Y, Kieny MP (2005) A review of vaccine research and development: human acute respiratory infections. Vaccine 23(50):5708–5724
7. Holmes KV (2003) SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111(11):1605–1609
8. Kim D, Kwon S, Rhee JW et al (2011a) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12:29
9. Kim D, Kwon HJ, Lee Y (2011b) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep 44(9):607–613
10. Kwon S, Kim D, Park BK et al (2012) Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS ONE 7(3):e33121
11. Lee KW, Jung J, Lee Y et al (2006) Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 43(13):2107–2118
12. Li F (2015a) Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 89(4):1954–1964
13. Li Y, Wan Y, Liu P et al (2015b) A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 25(11):1237–1249
14. Lu G, Hu Y, Wang Q et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227–231
15. Lu L, Liu Q, Zhu Y et al (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:3067
16. Lui PY, Wong LY, Fung CL et al (2016) Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerg Microbes Infect 5:e39
17. Mackay IM, Arden KE (2017) An opportunistic pathogen afforded ample opportunities: Middle East respiratory syndrome coronavirus. Viruses. 10.3390/v9120369
18. Mustafa S, Balkhy H, Gabere MN (2018) Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review. J Infect Public Health 11(1):9–17
19. Ohnuma K, Haagmans BL, Hatano R et al (2013) Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol 87(24):13892–13899
20. Park BK, Choi SH, Kim YE et al (2015) Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34(2):101–109
21. Peiris JS, Guan Y, Yuen KY (2004) Severe acute respiratory syndrome. Nat Med 10(12 Suppl):S88–S97
22. Raj VS, Mou H, Smits SL et al (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251–254
23. Raj VS, Smits SL, Provacia LB et al (2014) Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 88(3):1834–1838
24. Rhee JW, Kim D, Park BK et al (2012) Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice. PLoS ONE 7(11):e48750
25. Scobey T, Yount BL, Sims AC et al (2013) Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci USA 110(40):16157–16162
26. Tao X, Garron T, Agrawal AS et al (2015) Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 90(1):57–67
27. The WHO MERS-CoV Research Group (2013) State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
28. van Boheemen S, de Graaf M, Lauber C et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 10.1128/mBio.00473-12
29. Wang L, Shi W, Joyce MG et al (2015) Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 6:7712
30. Wu G, Kim D, Kim JN et al (2018) A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Theranostics 8(1):78–91
31. Yang Y, Zhang L, Geng H et al (2013) The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4(12):951–961
32. Yin Y, Wunderink RG (2018) MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 23(2):130–137
33. Yokoyama WM, Christensen M, Santos GD, Miller D (2006) Production of monoclonal antibodies. Curr Protoc Immunol. 10.1002/0471142735.im0205s74
34. Zaki AM, van Boheemen S, Bestebroer TM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820
35. Zhang EX, Oh OS, See W et al (2016) Assessment of the risk posed to Singapore by the 2015 Middle East respiratory syndrome outbreak in the Republic of Korea. Western Pac Surveill Response J 7(2):17–25